NASDAQ:INNTInnovate Biopharmaceuticals Stock Price, Forecast & News

$0.57

-0.01 (-1.74 %)

(As of 06/3/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.55

Now: $0.57▼

$0.58

50-Day Range

$0.44

MA: $0.56▼

$0.74

52-Week Range

$0.37

Now: $0.57▼

$1.67

Volume163,659 shs

Average Volume525,982 shs

Market Capitalization$23.39 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.39

Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Innovate Biopharmaceuticals.

2.4 Community Rank

Outperform Votes
Innovate Biopharmaceuticals has received 203 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Innovate Biopharmaceuticals has received 214 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Innovate Biopharmaceuticals has received 51.32% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Innovate Biopharmaceuticals and other stocks. Vote “Outperform” if you believe INNT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INNT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Innovate Biopharmaceuticals does not currently pay a dividend.
Dividend Growth
Innovate Biopharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Innovate Biopharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.90% of the stock of Innovate Biopharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 5.88% of the stock of Innovate Biopharmaceuticals is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Innovate Biopharmaceuticals are expected to grow in the coming year, from ($0.68) to $0.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Innovate Biopharmaceuticals is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Innovate Biopharmaceuticals is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

0.61 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:INNT

Previous Symbol

CUSIPN/A

CIK1551986

Webwww.innovatebiopharma.com

Phone919-275-1933

Debt

Debt-to-Equity RatioN/A

Current Ratio0.35

Quick Ratio0.35

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.27) per share

Price / Book-2.10

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-27,050,000.00

Net MarginsN/A

Return on EquityN/A

Return on Assets-234.42%

Miscellaneous

Employees8

Outstanding Shares41,325,000

Market Cap$23.39 million

Next Earnings DateN/A

OptionableOptionable

Receive INNT News and Ratings via Email

Sign-up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.

Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions

How has Innovate Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Innovate Biopharmaceuticals' stock was trading at $0.4715 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INNT shares have increased by 20.1% and is now trading at $0.5661. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Innovate Biopharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Innovate Biopharmaceuticals.

How were Innovate Biopharmaceuticals' earnings last quarter?

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) issued its quarterly earnings data on Monday, March, 18th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). View Innovate Biopharmaceuticals' earnings history.

Has Innovate Biopharmaceuticals been receiving favorable news coverage?

Headlines about INNT stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Innovate Biopharmaceuticals earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutInnovate Biopharmaceuticals.

Who are some of Innovate Biopharmaceuticals' key competitors?

Some companies that are related to Innovate Biopharmaceuticals include Corvus Pharmaceuticals (CRVS), CannTrust (CTST), Genprex (GNPX), Catalyst Biosciences (CBIO), Aptorum Group (APM), Clearside Biomedical (CLSD), Onconova Therapeutics (ONTX), Oncolytics Biotech (ONCY), Sesen Bio (SESN), Milestone Pharmaceuticals (MIST), CV Sciences (CVSI), Bellerophon Therapeutics (BLPH), Otonomy (OTIC), Monopar Therapeutics (MNPR) and CTI BioPharma (CTIC). View all competitors.

What other stocks do shareholders of Innovate Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), Iterum Therapeutics (ITRM), Axsome Therapeutics (AXSM), Alibaba Group (BABA), Canopy Growth (CGC), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Avid Bioservices (CDMO).

Who are Innovate Biopharmaceuticals' key executives?

Innovate Biopharmaceuticals' management team includes the following people:

Mr. Sandeep Laumas M.D., CEO & Exec. Chairman (Age 50)
Mr. Jay P. Madan M.S., Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director (Age 53)
Dr. Christopher P. Prior, Consultant (Age 66)
Jerry Gardner M.D., Head of Clinical Strategy
Dr. Patrick H. Griffin, Chief Medical Officer (Age 64)

What is Innovate Biopharmaceuticals' stock symbol?

Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."

How do I buy shares of Innovate Biopharmaceuticals?

Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innovate Biopharmaceuticals' stock price today?

One share of INNT stock can currently be purchased for approximately $0.57.

How big of a company is Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals has a market capitalization of $23.39 million. Innovate Biopharmaceuticals employs 8 workers across the globe.

What is Innovate Biopharmaceuticals' official website?

The official website for Innovate Biopharmaceuticals is www.innovatebiopharma.com.

How can I contact Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff